These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26092062)

  • 1. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
    Harvey NC; Kanis JA; Odén A; Nakamura T; Shiraki M; Sugimoto T; Kuroda T; Johansson H; McCloskey EV
    Osteoporos Int; 2015 Sep; 26(9):2347-53. PubMed ID: 26092062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
    Harvey NC; Kanis JA; Odén A; Burge RT; Mitlak BH; Johansson H; McCloskey EV
    Osteoporos Int; 2015 Nov; 26(11):2677-84. PubMed ID: 26092063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Osteoporos Int; 2011 Aug; 22(8):2347-55. PubMed ID: 21287148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
    Kaufman JM; Palacios S; Silverman S; Sutradhar S; Chines A
    Osteoporos Int; 2013 Oct; 24(10):2561-9. PubMed ID: 23595562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
    McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
    Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of teriparatide compared with risedronate on FRAX
    Body JJ; Marin F; Kendler DL; Zerbini CAF; López-Romero P; Möricke R; Casado E; Fahrleitner-Pammer A; Stepan JJ; Lespessailles E; Minisola S; Geusens P
    Osteoporos Int; 2020 Oct; 31(10):1935-1942. PubMed ID: 32474650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.
    McCloskey EV; Johansson H; Oden A; Austin M; Siris E; Wang A; Lewiecki EM; Lorenc R; Libanati C; Kanis JA
    J Bone Miner Res; 2012 Jul; 27(7):1480-6. PubMed ID: 22431426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis.
    Fujita T; Fukunaga M; Itabashi A; Tsutani K; Nakamura T
    Calcif Tissue Int; 2014 Feb; 94(2):170-5. PubMed ID: 23963633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.
    Hagino H; Sugimoto T; Tanaka S; Sasaki K; Sone T; Nakamura T; Soen S; Mori S
    Osteoporos Int; 2021 Nov; 32(11):2301-2311. PubMed ID: 34002252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
    Reginster JY; Kaufman JM; Goemaere S; Devogelaer JP; Benhamou CL; Felsenberg D; Diaz-Curiel M; Brandi ML; Badurski J; Wark J; Balogh A; Bruyère O; Roux C
    Osteoporos Int; 2012 Mar; 23(3):1115-22. PubMed ID: 22124575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study.
    McCloskey EV; Johansson H; Harvey NC; Lorentzon M; Shi Y; Kanis JA
    Osteoporos Int; 2021 Aug; 32(8):1601-1608. PubMed ID: 33537844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment responses with once-weekly teriparatide therapy for osteoporosis.
    Shiraki M; Ueda S; Sugimoto T; Kuroda T; Nakamura T
    Osteoporos Int; 2016 Oct; 27(10):3057-62. PubMed ID: 27234671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
    Leslie WD; Martineau P; Bryanton M; Lix LM
    Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FRAX- vs. T-score-based intervention thresholds for osteoporosis.
    Johansson H; Azizieh F; Al Ali N; Alessa T; Harvey NC; McCloskey E; Kanis JA
    Osteoporos Int; 2017 Nov; 28(11):3099-3105. PubMed ID: 28782072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.